These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 24037548)

  • 1. Low levels of antibodies against oxidized but not nonoxidized cardiolipin and phosphatidylserine are associated with atherosclerotic plaques in systemic lupus erythematosus.
    Su J; Frostegård AG; Hua X; Gustafsson T; Jogestrand T; Hafström I; Frostegård J
    J Rheumatol; 2013 Nov; 40(11):1856-64. PubMed ID: 24037548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased prevalence of vulnerable atherosclerotic plaques and low levels of natural IgM antibodies against phosphorylcholine in patients with systemic lupus erythematosus.
    Anania C; Gustafsson T; Hua X; Su J; Vikström M; de Faire U; Heimbürger M; Jogestrand T; Frostegård J
    Arthritis Res Ther; 2010; 12(6):R214. PubMed ID: 21092251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibodies against native and oxidized cardiolipin and phosphatidylserine and phosphorylcholine in atherosclerosis development.
    Frostegård AG; Su J; Hua X; Vikström M; de Faire U; Frostegård J
    PLoS One; 2014; 9(12):e111764. PubMed ID: 25473948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IgM antibodies against malondialdehyde and phosphorylcholine are together strong protection markers for atherosclerosis in systemic lupus erythematosus: Regulation and underlying mechanisms.
    Rahman M; Sing S; Golabkesh Z; Fiskesund R; Gustafsson T; Jogestrand T; Frostegård AG; Hafström I; Liu A; Frostegård J
    Clin Immunol; 2016 May; 166-167():27-37. PubMed ID: 27102765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arteriosclerosis obliterans associated with anti-cardiolipin antibody/beta2-glycoprotein I antibodies as a strong risk factor for ischaemic heart disease in patients with systemic lupus erythematosus.
    Nojima J; Masuda Y; Iwatani Y; Kuratsune H; Watanabe Y; Suehisa E; Takano T; Hidaka Y; Kanakura Y
    Rheumatology (Oxford); 2008 May; 47(5):684-9. PubMed ID: 18375400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The value of IgA antiphospholipid testing for diagnosis of antiphospholipid (Hughes) syndrome in systemic lupus erythematosus.
    Bertolaccini ML; Atsumi T; Escudero Contreras A; Khamashta MA; Hughes GR
    J Rheumatol; 2001 Dec; 28(12):2637-43. PubMed ID: 11764209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High frequency of abnormal levels of IgA anti-beta2-glycoprotein I antibodies in patients with systemic lupus erythematosus: relationship with antiphospholipid syndrome.
    Fanopoulos D; Teodorescu MR; Varga J; Teodorescu M
    J Rheumatol; 1998 Apr; 25(4):675-80. PubMed ID: 9558168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-beta2-glycoprotein I: prevalence, clinical correlations, and importance of persistent positivity in patients with antiphospholipid syndrome and systemic lupus erythematosus.
    Danowski A; Kickler TS; Petri M
    J Rheumatol; 2006 Sep; 33(9):1775-9. PubMed ID: 16960938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The presence of anti-phosphatidylserine/prothrombin antibodies as risk factor for both arterial and venous thrombosis in patients with systemic lupus erythematosus.
    Nojima J; Iwatani Y; Suehisa E; Kuratsune H; Kanakura Y
    Haematologica; 2006 May; 91(5):699-702. PubMed ID: 16627257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Risk factors of thickened intima-media and atherosclerotic plaque development in carotid arteries in patients with systemic lupus erythematosus].
    Fischer K
    Ann Acad Med Stetin; 2008; 54(2):22-32. PubMed ID: 19374227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of rare anti-phospholipid/protein co-factor autoantibodies in patients with systemic lupus erythematosus.
    Szodoray P; Tarr T; Tumpek J; Kappelmayer J; Lakos G; Poor G; Szegedi G; Kiss E
    Autoimmunity; 2009 Sep; 42(6):497-506. PubMed ID: 19626489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid peroxidation is enhanced in patients with systemic lupus erythematosus and is associated with arterial and renal disease manifestations.
    Frostegård J; Svenungsson E; Wu R; Gunnarsson I; Lundberg IE; Klareskog L; Hörkkö S; Witztum JL
    Arthritis Rheum; 2005 Jan; 52(1):192-200. PubMed ID: 15641060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of antibodies to beta2-glycoprotein I in systemic lupus erythematosus and their association with antiphospholipid antibody syndrome criteria: a single center study and literature review.
    Bruce IN; Clark-Soloninka CA; Spitzer KA; Gladman DD; Urowitz MB; Laskin CA
    J Rheumatol; 2000 Dec; 27(12):2833-7. PubMed ID: 11128672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-phospholipid antibodies in HIV infection and SLE with or without anti-phospholipid syndrome: comparisons of phospholipid specificity, avidity and reactivity with beta2-GPI.
    Petrovas C; Vlachoyiannopoulos PG; Kordossis T; Moutsopoulos HM
    J Autoimmun; 1999 Nov; 13(3):347-55. PubMed ID: 10550222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Excess atherosclerosis in systemic lupus erythematosus,-A matter of renal involvement: Case control study of 281 SLE patients and 281 individually matched population controls.
    Gustafsson JT; Herlitz Lindberg M; Gunnarsson I; Pettersson S; Elvin K; Öhrvik J; Larsson A; Jensen-Urstad K; Svenungsson E
    PLoS One; 2017; 12(4):e0174572. PubMed ID: 28414714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strong correlation between the prevalence of cerebral infarction and the presence of anti-cardiolipin/beta2-glycoprotein I and anti-phosphatidylserine/prothrombin antibodies--Co-existence of these antibodies enhances ADP-induced platelet activation in vitro.
    Nojima J; Kuratsune H; Suehisa E; Kitani T; Iwatani Y; Kanakura Y
    Thromb Haemost; 2004 May; 91(5):967-76. PubMed ID: 15116258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and clinical associations of lupus anticoagulant, anticardiolipin antibodies, and anti-beta2-glycoprotein I antibodies in patients with systemic lupus erythematosus.
    Woo KS; Kim KE; Kim JM; Han JY; Chung WT; Kim KH
    Korean J Lab Med; 2010 Feb; 30(1):38-44. PubMed ID: 20197721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The association of antibodies to cardiolipin, beta 2-glycoprotein I, prothrombin, and oxidized low-density lipoprotein with thrombosis in 292 patients with familial and sporadic systemic lupus erythematosus.
    Koskenmies S; Vaarala O; Widen E; Kere J; Palosuo T; Julkunen H
    Scand J Rheumatol; 2004; 33(4):246-52. PubMed ID: 15370721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxidized low-density lipoprotein and beta2-glycoprotein I in patients with systemic lupus erythematosus and increased carotid intima-media thickness: implications in autoimmune-mediated atherosclerosis.
    Lopez LR; Salazar-Paramo M; Palafox-Sanchez C; Hurley BL; Matsuura E; Garcia-De La Torre I
    Lupus; 2006; 15(2):80-6. PubMed ID: 16539278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autoantibody profiling reveals four protein candidate autoantigens associated with systemic lupus erythematosus.
    Frostegård J; Hellström C; Nilsson P; Frostegård AG; Ajeganova S
    Lupus; 2018 Sep; 27(10):1670-1678. PubMed ID: 30041579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.